During the past 20 years, hundreds of thousands of women with breast cancer have taken the drug Herceptin, typically for a year or more. The medicine, used to treat an aggressive form of the disease, ...
Forget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz ...
The European Society for Medical Oncology kicks off its five-day Vienna conference Friday, and Roche’s stock ticker may be expected to pulse with the conversations. That is, particularly if findings ...
-- Phase II Study Evaluating a Novel Targeted Combination Regimen Showed Promising Results in the Neoadjuvant (Pre-surgery) Setting -- “The findings of the NEOSPHERE study suggested that this new ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.S. Food and Drug Administration (FDA) has approved Herceptin ® ...
Treating women with early stage breast cancer with a combination of chemotherapy and the molecularly targeted drug Herceptin significantly increases survival in patients with a specific genetic ...
Sometimes less may be better when it comes to treatment for breast cancer. A new study finds that women who have been diagnosed with early-stage HER2-positive breast cancer did just as well with six ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback